Kanyos Bio
Kanyos Bio is a privately held, preclinical-stage biotechnology company founded in 2015 in Cambridge, MA, focused on developing antigen-specific immune tolerance technology for two specific autoimmune indications, backed by Novartis Venture Fund and Novo Ventures.
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Kanyos Bio firmographics
Firmographics- Name
- Kanyos Bio
- Website
- https://kanyos.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Kanyos Bio is a privately held, preclinical-stage biotechnology company founded in 2015 in Cambridge, MA, focused on developing antigen-specific immune tolerance technology for two specific autoimmune indications, backed by Novartis Venture Fund and Novo Ventures.
- Ownership category
- akta.pro rank
Kanyos Bio industry classification
Industry- Product category
- Autoimmune Disease Biotherapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industry
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
Keywords
Where Kanyos Bio is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Kanyos Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Kanyos Bio product offering
Product offeringCore offering
Kanyos Bio is developing antigen-specific immune tolerance technology intended to treat two specific autoimmune indications. The company's work is centered on engineering immune tolerance to targeted antigens as a therapeutic approach for autoimmune disease. No commercial products, clinical-stage assets, or product page details are publicly available.
Differentiator
Problem solved
Functional benefit
Companies that use Kanyos Bio
Customer profileIdeal customer profiles1 record
Kanyos Bio technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Kanyos Bio competitors and assessment
Company assessmentDirect peers
- Anokion: Anokion is a clinical-stage biotech developing antigen-specific immune tolerance therapies for autoimmune diseases (e.g., multiple sclerosis, celiac disease). It is the closest direct peer to Kanyos Bio given the shared antigen-specific tolerance platform and autoimmune focus.
- Cour Pharmaceuticals: Cour Pharmaceuticals develops antigen-specific nanoparticle immune tolerance therapies for autoimmune and inflammatory indications such as celiac disease, primary biliary cholangitis, and peanut allergy. It competes in the same antigen-specific immune tolerance niche as Kanyos Bio.
- Selecta Biosciences: Selecta Biosciences (now ImmunoMix-affiliated) developed tolerogenic ImmTOR and antigen-specific tolerance platforms for autoimmune disease and biologic immunogenicity, directly comparable to Kanyos Bio's stated mechanism of action.
- Tolerion: Tolerion is developing antigen-specific immune tolerance therapies for autoimmune indications including type 1 diabetes. It is a direct platform competitor with similar therapeutic ambitions to Kanyos Bio.
- Abata Therapeutics: Abata Therapeutics is pioneering antigen-specific regulatory T-cell (Treg) therapies for autoimmune diseases such as multiple sclerosis and type 1 diabetes, sharing Kanyos Bio's antigen-specific tolerance modality and autoimmune focus.
Emerging players
- Parvus Therapeutics: Parvus Therapeutics develops Navacim nanoparticle therapies that induce antigen-specific immune tolerance for autoimmune disease, including inflammatory bowel disease. It uses a distinct delivery technology but targets the same biological mechanism as Kanyos Bio.
- ImmusanT: ImmusanT developed Nexvax2, a peptide-based antigen-specific immunotherapy for celiac disease, an autoimmune indication. It is a partial-overlap peer in antigen-specific tolerance, though its lead program had clinical setbacks.
Broad incumbents
- Provention Bio (Sanofi): Provention Bio (acquired by Sanofi) developed autoimmune therapies including teplizumab for type 1 diabetes. It serves as a broad incumbent in autoimmune therapeutics and an obvious large-pharma acquirer of antigen-specific tolerance assets of the kind Kanyos Bio is pursuing.
Market position
Customer concentration
Kanyos Bio social profiles
Digital presenceKanyos Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kanyos Bio leadership team
Management profileNumber of profiles
Profiles1 record
Kanyos Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kanyos Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kanyos Bio
What does Kanyos Bio do?
Kanyos Bio is developing antigen-specific immune tolerance technology intended to treat two specific autoimmune indications. The company's work is centered on engineering immune tolerance to targeted antigens as a therapeutic approach for autoimmune disease. No commercial products, clinical-stage assets, or product page details are publicly available.
When was Kanyos Bio founded?
Kanyos Bio was founded in 2015. It employs 1 to 10 people.
Where is Kanyos Bio based?
Kanyos Bio is headquartered in Cambridge, United States, in the North America region.
Who are Kanyos Bio's main competitors?
Direct peers on record are Anokion, Cour Pharmaceuticals, Selecta Biosciences, Tolerion and Abata Therapeutics. Emerging players are Parvus Therapeutics and ImmusanT. Provention Bio (Sanofi) is listed as a broad incumbent.
Does Kanyos Bio have an API?
No public API is recorded for Kanyos Bio.
What industry is Kanyos Bio in?
Kanyos Bio's product category is Autoimmune Disease Biotherapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins. Its NAICS code is 325414 and its SIC code is 2836.